Multiple Myeloma

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.

Rachid Baz, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses how treatment approaches vary for patients with multiple myeloma.

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab in multiple myeloma.

Prashant Kapoor, MD, discusses the importance of minimal residual disease negativity, using International Myeloma Working Group criteria, and field-changing pivotal data in multiple myeloma.

Shaji Kumar, MD, discusses novel therapies for patients with multiple myeloma in detail, the sequencing challenges ahead, and which current agents pose the greatest challenge.

Ruben Niesvizky, MD, discusses some of the exciting advances, the potential of chimeric antigen receptor T-cell therapy, and emerging combination regimens on the horizon in multiple myeloma.

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.

Prashant Kapoor, MD, hematologic oncologist, Mayo Clinic, shares advice for community oncologists who are treating patients with multiple myeloma.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.

The European Commission has approved daratumumab for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma following at least 1 prior therapy.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses some of the recent advancements, including FDA approvals, in the field of multiple myeloma.

A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses combining daratumumab (Darzalex) for patients with multiple myeloma.

Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD), when used in conjunction with stem cell transplantation, extended progression-free survival compared with RVD alone in patients with multiple myeloma.

There is no comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of myeloma patients. The UK Myeloma Forum and the British Society for Haematology set out to address this need and published such a guideline in a recent issue of the British Journal of Hematology.

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses challenges facing the field of multiple myeloma.

The past several decades have witnessed a dramatic improvement in the treatment of patients with multiple myeloma, the second most common type of hematologic malignancy. A better understanding of the biology of this disease and the introduction of a wealth of novel drug classes has more than doubled median survival times.